Editorial Board
Submit Manuscript
Submit manuscript at Online Submission System or send as an e-mail attachment to the Editorial Office at manuscripts@longdom.org
Table of Contents
About the Journal
NLM ID:101676003
Immunotherapy is a treatment procedure which enhances or supress the body’s immune system to fight against a disease. Immunotherapies which enhance the immune response are called as activation immunotherapies and those which reduce or suppress the immune response are called as suppression immunotherapies. Immunotherapy is of many types but the major immunotherapies for cancer include Monoclonal antibodies, Cancer vaccines and Non-specific immunotherapies.
The Journal of immunotherapy covers a wide range of topics related to allergy immunotherapy, cancer immunotherapy, immunotherapy for Kidney failure, lung cancer immunotherapy, melanoma immunotherapy, prostate cancer immunotherapy, sublingual immunotherapy, immunotherapy for HIV, immunotherapy for autoimmune diseases and transplantation, biomarkers for cancer immunotherapy, drug delivery systems and drug interactions, novel immunotherapeutic agents and immunotherapeutics clinical trials for immunotherapy etc. The journal also covers immunotherapeutic products, regulatory and FDI guidelines for immunotherapeutics and immunotherapy for kidney failure.
The journal of immunotherapy accepts all types of articles including research, review, case reports, commentaries, hypotheses, meeting reports, editorials and short reports.
Journal of immunotherapy is using Editorial Tracking System for quality in review process. It is an online manuscript submission, review and tracking system used by most of the best open access journals. Review processing is performed by the editorial board members of Journal or outside experts; at least two independent reviewers approval followed by editor's approval is required for acceptance of any citable manuscript.
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
blog
Longdom Publishing SL organizes 1000+ conferences every year across USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ open access journals which contains over 50000 eminent personalities, reputed scientists as editorial board members. Authors are requested to submit manuscript on Online Submission System , manuscripts@longdom.org
Fast Editorial Review Process
Immunotherapy: Open Access is participating in the Fast Editorial Execution and Review Process (FEE-Review Process) with an additional prepayment of $99 apart from the regular article processing fee. Fast Editorial Execution and Review Process is a special service for the article that enables it to get a faster response in the pre-review stage from the handling editor as well as a review from the reviewer. An author can get a faster response of pre-review maximum in 3 days since submission, and a review process by the reviewer maximum in 5 days, followed by revision/publication in 2 days. If the article gets notified for revision by the handling editor, then it will take another 5 days for external review by the previous reviewer or alternative reviewer.
Acceptance of manuscripts is driven entirely by handling editorial team considerations and independent peer-review, ensuring the highest standards are maintained no matter the route to regular peer-reviewed publication or a fast editorial review process. The handling editor and the article contributor are responsible for adhering to scientific standards. The article FEE-Review process of $99 will not be refunded even if the article is rejected or withdrawn for publication.
The corresponding author or institution/organization is responsible for making the manuscript FEE-Review Process payment. The additional FEE-Review Process payment covers the fast review processing and quick editorial decisions, and regular article publication covers the preparation in various formats for online publication, securing full-text inclusion in a number of permanent archives like HTML, XML, and PDF, and feeding to different indexing agencies.
h-index
Articles published in Immunotherapy: Open Access have been cited by esteemed scholars and scientists all around the world. Immunotherapy: Open Access has got h-index 9 , which means every article in Immunotherapy: Open Access has got 9 average citations.
Journal Highlights
Current Issue Highlights
Case Report
Use of an Anti-CD6 Antibody (Itolizumab) for the Treatment of COVID-19 Patients with Cytokine Release Syndrome Report of Three Cases
Lazaro Manuel Filgueira, Julio Betancourt Cervantes, Orlando Adolfo Lovelle, Carlos Herrera, Carlos Figueredo, Jorge Alain Caballero, Naivy Sanchez, Jorge Berrio, Geidy Lorenzo, Meylan Cepeda, Mayra Ramos, Danay Saavedra, Ana Laura Ane-Kouri, Zaima Mazorra*, Kalet Leon, Tania Crombet and Armando Caballero
Short Communication